Submissions for variant NM_000432.4(MYL2):c.275-14G>C

gnomAD frequency: 0.00025  dbSNP: rs375703502

Total submissions: 5

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000213783	SCV000272074	uncertain significance	not specified	2015-04-13	criteria provided, single submitter	clinical testing	The c.275-14G>C variant in MYL2 has not been previously reported in individuals with cardiomyopathy, but has been identified in 8/10392 of African chromosomes b y the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs375703502). This variant is located in the 3' splice region. Computational too ls do not suggest an impact to splicing; however, this information is not predic tive enough to rule out pathogenicity. In summary, the clinical significance of the c.275-14G>C variant is uncertain.
GeneDx	RCV000213783	SCV000717507	likely benign	not specified	2017-03-22	criteria provided, single submitter	clinical testing	This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Color Diagnostics, LLC DBA Color Health	RCV001182742	SCV001348300	likely benign	Cardiomyopathy	2018-11-16	criteria provided, single submitter	clinical testing
Labcorp Genetics (formerly Invitae), Labcorp	RCV002054960	SCV002479507	likely benign	Hypertrophic cardiomyopathy 10	2025-01-24	criteria provided, single submitter	clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000213783	SCV002600851	benign	not specified	2022-10-31	criteria provided, single submitter	clinical testing	Variant summary: MYL2 c.275-14G>C alters a nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 5.2e-05 in 251456 control chromosomes, predominantly at a frequency of 0.00068 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 9 fold of the estimated maximal expected allele frequency for a pathogenic variant in MYL2 causing Hypertrophic Cardiomyopathy phenotype (7.5e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. c.275-14G>C has been reported in the literature as a VUS in a setting of multigene testing in an individual affected with Hypertrophic Cardiomyopathy (e.g. Burstein_2021). This report does not provide unequivocal conclusions about association of the variant with Hypertrophic Cardiomyopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Three laboratories classified the variant as likely benign and one classified it as VUS. Based on the evidence outlined above, the variant was classified as benign.